<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glucocorticoid therapy in septic shock in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glucocorticoid therapy in septic shock in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Glucocorticoid therapy in septic shock in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David A Kaufman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Polly E Parsons, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The role of glucocorticoid therapy in patients with septic shock has evolved since the 1990s. The rationale for glucocorticoid administration, assessing adrenal reserve, and indications for glucocorticoid therapy are discussed in this topic review. Other aspects of the management of sepsis and septic shock are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>The rationale for glucocorticoid administration in patients with sepsis and septic shock is based upon data which suggest that critical illness induces a state of absolute or relative adrenal insufficiency that may contribute to shock. The purpose of administering glucocorticoids to patients with sepsis is to restore balance to the altered hypothalamic-pituitary-adrenal (HPA) axis with the goal of improving clinically meaningful outcomes such as mortality.</p><p class="headingAnchor" id="H303442606"><span class="h2">Mechanisms of adrenal insufficiency in sepsis</span><span class="headingEndMark"> — </span>There are several mechanisms through which critical illness affects cortisol levels and function including HPA activation (resulting in increased levels of circulating cortisol), HPA impairment (resulting in adrenocortical hyporesponsiveness), and glucocorticoid resistance.</p><p class="bulletIndent1"><span class="glyph">●</span>Activation of the HPA axis – Normal serum cortisol levels range between 5 and 24 mcg/dL, with significant variability depending upon the time of day [<a href="#rid1">1</a>]. In patients who are critically ill, diurnal variation is lost and serum cortisol increases, reaching levels as high as 40 to 50 mcg/dL  (<a class="graphic graphic_figure graphicRef66966" href="/z/d/graphic/66966.html" rel="external">figure 1</a>) [<a href="#rid2">2-6</a>]. Cortisol metabolism and function may also be considerably altered by other aspects of critical illness including reduced cortisol breakdown [<a href="#rid6">6</a>], reduced binding of cortisol to cortisol binding globulin (CBG) and albumin [<a href="#rid7">7,8</a>], increased glucocorticoid receptor affinity for cortisol, and peripheral conversion of precursors to cortisol [<a href="#rid9">9,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impairment of the HPA axis – Among critically ill patients, several factors are known to impair the HPA axis including head injury, central nervous system depressants, pituitary infarction, adrenal hemorrhage, infections, malignancy, previous glucocorticoid therapy, and several drugs like <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">etomidate</a> [<a href="#rid11">11-13</a>].</p><p></p><p class="bulletIndent1">However, the clinical importance of HPA impairment is uncertain. As an example, a randomized trial that compared <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">etomidate</a> with <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> for rapid sequence induction found that, despite an impaired response to adrenocorticotropic hormone (ACTH), etomidate was <strong>not</strong> associated with worse clinical outcomes [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoid resistance – Glucocorticoid resistance has also been proposed as a possible mechanism at play in patients with sepsis and septic shock. One study reported that compared with healthy controls, septic patients demonstrated higher expression levels of the beta-isoform of the glucocorticoid receptor, an isoform which is associated with steroid resistance [<a href="#rid15">15</a>]. However, functional differences were not observed. Other mechanisms of glucocorticoid resistance are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/549.html" rel="external">"Mechanisms and clinical implications of glucocorticoid resistance in asthma", section on 'Mechanisms of glucocorticoid resistance'</a>.)</p><p></p><p class="headingAnchor" id="H2015112861"><span class="h2">Critical illness-related corticosteroid insufficiency</span><span class="headingEndMark"> — </span>It is thought that absolute adrenal insufficiency is rare among critically ill patients, with an incidence estimated to be ≤3 percent [<a href="#rid16">16</a>]. However, the term relative adrenal insufficiency (ie, suboptimal cortisol production for total body demands) has been coined to take into account the high prevalence of HPA dysfunction in those who are critically ill. This condition has also been termed "critical illness-related corticosteroid insufficiency (CIRCI)" [<a href="#rid17">17</a>]. However, there is no consensus about the diagnostic criteria of CIRCI. In addition, there exists considerable disagreement over what cortisol level is "normal" or "appropriate" in septic shock, what constitutes an adequate response to ACTH, and what dose of synthetic ACTH should be used for stimulation testing. We believe that it is uncertain whether "relative adrenal insufficiency" is a true diagnostic entity, since a clear definition is lacking and the cortisol assays that are available at most clinical laboratories are unreliable in the critically ill patient.</p><p class="headingAnchor" id="H5"><span class="h2">Should adrenal reserve be assessed?</span><span class="headingEndMark"> — </span>In general, most clinicians do <strong>not</strong> rely on laboratory testing to select glucocorticoid replacement therapy in patients with septic shock. This is because laboratory assays of plasma cortisol concentration and response to ACTH stimulation are unreliable in critically ill patients. In addition, in major randomized trials, baseline cortisol levels and the <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">ACTH stimulation test</a> have failed to consistently identify patients with septic shock who benefit from glucocorticoid use (see <a class="local">'Efficacy'</a> below). With this caveat in mind, for clinicians who wish to assess adrenal reserve in critically ill patients, international guidelines from the Society of Critical Care Medicine and European Society of Intensive Care Medicine [<a href="#rid17">17</a>] endorse the use of a change in baseline cortisol at 60 min of &lt;9 mcg/dL after cosyntropin (250 mcg; ie, high-dose ACTH stimulation) administration and a random plasma cortisol of ≤10 mcg/dL as indicators of likely adrenal insufficiency in critically ill patients.</p><p>Studies describing the diagnostic and prognostic performance of these tests in critically ill patients are discussed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Random serum cortisol</strong> – Total serum cortisol levels vary widely in patients with septic shock [<a href="#rid5">5,18-23</a>]. There is no robust relationship between serum cortisol levels and mortality in patients with septic shock [<a href="#rid19">19,21,24-31</a>]. One prospective study of 101 patients with sepsis reported that the best predictor of adrenal insufficiency (as measured by an overnight <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">ACTH stimulation test</a>) was baseline random cortisol level of ≤10 microg/dL or a change of cortisol of &lt;9 microg/dL [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Free cortisol</strong> – In critically ill patients there is a shift from inactive protein-bound cortisol to physiologically active free cortisol. It has been proposed that free cortisol more accurately reflects HPA axis activation in critically ill patients [<a href="#rid32">32</a>]. However, standard assays for plasma cortisol measure total (free + bound) plasma cortisol and free cortisol assays are not available at most clinical centers [<a href="#rid33">33</a>]. Thus, most experts agree that standard assays underestimate HPA axis activity in this population.</p><p></p><p class="bulletIndent1">Supporting free cortisol as a more accurate measurement of adrenal insufficiency in critically ill patients are the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One prospective study reported that critically ill patients had free cortisol levels that were 7 to 10 times higher than healthy volunteers compared with total serum cortisol concentrations that were only two to three times higher [<a href="#rid32">32</a>]. However, this study was limited by the lack of inclusion of patients with septic shock and the omission of data describing hemodynamic instability at the time of plasma cortisol sampling.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another prospective study, baseline free cortisol levels reflected the severity of illness more closely than total cortisol levels [<a href="#rid34">34</a>]; free cortisol levels were 186 nmol/L in patients with septic shock, 29 nmol/L in patients with sepsis, and 13 nmol/L in healthy controls while total cortisol levels were 880 nmol/L in patients with septic shock, 417 nmol/L in patients with sepsis, and 352 nmol/L in healthy controls.</p><p></p><p class="bulletIndent1">Further complicating matters, one study suggested that plasma levels of cortisol (free or total) had only moderate correlation with tissue availability of the hormone, suggesting that during critical illness, blood levels of cortisol poorly reflect the amount of hormone available to target tissues [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACTH stimulation tests</strong> — The ACTH (cosyntropin) stimulation test requires that a baseline serum cortisol be drawn, synthetic ACTH (cosyntropin) be administered intravenously, and serum cortisol levels then be drawn 30 and 60 minutes later. </p><p></p><p class="bulletIndent1">Despite extensive investigation, ACTH stimulation tests are thought to be unreliable in critically ill patients for several reasons:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some critically ill individuals have spontaneous increases in their serum cortisol of ≥9 mcg/dL WITHOUT cosyntropin stimulation [<a href="#rid36">36</a>]. Thus, this threshold may not be clinically helpful.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ACTH stimulation tests may give inconsistent results in the same individuals if performed on more than one occasion [<a href="#rid19">19,37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Standard immunoassays appear to correlate poorly with the reference standard (mass spectrometry) in septic shock with one study reporting that approximately 27 percent of <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">ACTH stimulation test</a> samples were incorrectly classified by immunoassays compared with mass spectrometry measurements [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">Etomidate</a>, which suppresses the HPA axis [<a href="#rid14">14,39</a>], if used for intubating patients with septic shock, can interfere with the results of ACTH stimulation.</p><p></p><p class="bulletIndent1">Studies using high-dose ACTH stimulation (250 mcg cosyntropin) have yielded variable results in septic shock [<a href="#rid19">19,22,31,40,41</a>]. For example, one prospective cohort study of 189 patients with septic shock reported that a baseline serum cortisol level &gt;34 mcg/dL and a maximum increase in cortisol of ≤9 mcg/dL were identified as risk factors for death [<a href="#rid41">41</a>]. Similarly, another retrospective cohort study of 477 patients with severe sepsis or septic shock reported that nonsurvivors had a higher baseline cortisol level (30 versus 24 mcg/dL) and a smaller cortisol increase (6 versus 11 mcg/dL) than survivors [<a href="#rid42">42</a>]. In contrast, another study found that patients with either a baseline cortisol level &lt;15 mcg/dL or a cortisol increase ≤9 mcg/dL had a higher mortality, longer duration of shock, or shorter survival time.</p><p></p><p class="bulletIndent1">Low-dose (1 mcg) ACTH stimulation testing has been compared with high-dose ACTH stimulation testing in patients with septic shock. In a prospective cohort study of 59 patients with septic shock, adrenal insufficiency (defined as post-cosyntropin serum cortisol of &lt;18 mcg/dL) was detected in more patients by low-dose ACTH testing than high-dose ACTH testing (22 versus 8 percent) [<a href="#rid43">43</a>]. Low-dose testing was superior compared with high-dose testing at identifying steroid responders (ie, patients able to maintain a mean arterial blood pressure &gt;65 mmHg without <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> infusion within 24 hours) from non-responders. In another retrospective study, non-responders to the low-dose test had a lower survival rate than responders to both tests (27 versus 47 percent) [<a href="#rid44">44</a>]. Low-dose testing identified a subgroup of patients in septic shock with inadequate adrenal reserve who had a worse outcome and would have been missed by the high-dose test; in addition, non-responders of either low- or high-dose stimulation were less likely to survive than responders. While these studies suggest that low-dose stimulation testing may predict death, further studies are needed to validate these findings.</p><p></p><p class="bulletIndent1">ACTH stimulation testing for non-critically-ill patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults", section on 'ACTH stimulation tests'</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">GLUCOCORTICOID THERAPY</span><span class="headingEndMark"> — </span>The major challenge associated with the administration of glucocorticoids to patients with sepsis is to select those who are likely to benefit.</p><p class="headingAnchor" id="H3425672513"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>When considering patients with sepsis and septic shock for glucocorticoid therapy, we generally use the following guidelines:</p><p class="bulletIndent1"><span class="glyph">●</span>For adult patients with septic shock, we suggest <strong>not</strong> routinely using intravenous glucocorticoid therapy as part of initial therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We use glucocorticoid therapy on a case-by-case basis in patients with refractory shock (defined as a systolic blood pressure &lt;90 mmHg for more than one hour following both adequate fluid resuscitation and vasopressor administration).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the decision is made to use glucocorticoid therapy, we suggest <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> alone (&lt;400 mg per day in divided doses) rather than combined therapy with <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a>. However, addition of fludrocortisone (50 mcg via gastric tube once daily) is a reasonable alternative based upon some trials that showed a mortality benefit [<a href="#rid45">45,46</a>].</p><p></p><p>This approach is based upon randomized trials and meta-analyses that have consistently demonstrated that while glucocorticoid therapy leads to faster resolution of shock, there appears to be minimal or no effect on mortality; in addition, benefit is more likely to be seen in those who are severely ill rather than those with mild illness [<a href="#rid45">45-52</a>]. Our recommendation is, in principle, consistent with that of other experts who state that either option of administering or not administering corticosteroids is reasonable [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>In the 1980s, three randomized studies of high-dose glucocorticoids (eg, 30 mg/kg of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>) showed no mortality benefit (at 14 days) in critically ill patients [<a href="#rid54">54-56</a>]. In the 1990s, three small trials showed that compared with placebo, low-dose <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> (eg, 200 to 400 mg per day) in patients with septic shock resulted in faster shock reversal (ie, faster pressor withdrawal) [<a href="#rid57">57-59</a>]. These trials prompted larger randomized trials, most of which have confirmed faster resolution of shock with no or minimal mortality benefit.</p><p class="headingAnchor" id="H560835110"><span class="h3">Studies that showed benefit</span><span class="headingEndMark"> — </span>Two major randomized trials demonstrated faster resolution of shock together with a mortality benefit from the administration of both <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> and <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>French trial</strong> – In the 2002 French study, 300 patients were randomly assigned to receive placebo or <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> (50 mg intravenously every six hours) plus <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> (50 mcg enterally once a day) for vasopressor-dependent septic shock [<a href="#rid45">45</a>]. Treatment began within eight hours of the onset of septic shock and continued for seven days. Hydrocortisone/fludrocortisone administration decreased 28-day mortality (55 versus 61 percent) and resulted in faster shock reversal (57 versus 40 percent). These benefits were maintained among patients with inadequate adrenal reserve (maximum increase in serum cortisol of &lt;9 mcg/dL on a high dose ACTH test) while no benefit was demonstrated in those who had an adequate adrenal reserve. The trial was criticized for its high placebo-group mortality [<a href="#rid60">60-62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHHS) </strong>– The same group published another trial in 2018. In this multicenter trial, 1241 patients with severe septic shock (mixed surgical and medical patients) on vasopressors, most of whom were mechanically ventilated, were randomized to receive placebo or <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> (200 mg per day in four divided doses) plus <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> (50 micrograms via nasogastric tube daily) for seven days without tapering [<a href="#rid46">46</a>]. Hydrocortisone/fludrocortisone administration decreased 90-day mortality (43 versus 49 percent) and 180-day mortality (47 versus 53 percent), and increased vasopressor-free days (17 versus 15 days). Also improved by hydrocortisone/fludrocortisone administration were ICU discharge (35 versus 41 percent), hospital discharge (39 versus 45 percent), and organ failure-free days (14 versus 12 days). There was no increase in the rates of superinfection or neurologic sequelae but corticosteroids resulted in an increase in the rate of hyperglycemia (89 versus 83 percent).</p><p></p><p>Differences between these two trials [<a href="#rid45">45,46</a>] and those that did not show a mortality benefit (see <a class="local">'Studies that showed no mortality benefit'</a> below) may be explained by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Sicker patients – Both the initial French trial and APROCCHHS were comprised of a sicker group of patients as evidenced by the high simplified acute physiology II scores (SAPS II), greater need for higher doses of vasopressors at the time of enrollment, and higher mortality risk. (See  <a class="medical medical_review" href="/z/d/html/1655.html" rel="external">"Predictive scoring systems in the intensive care unit"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Different sepsis sources – Sources of infections may have also been different. For example, APROCCHSS had fewer patients with abdominal infection following surgery and had more patients with lung infections than trials that showed benefit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Addition of mineralocorticoid – Both studies included the addition of <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> to <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> as opposed to hydrocortisone alone. While one retrospective study suggested benefit [<a href="#rid63">63</a>], the biologic plausibility of additional mineralocorticoid to hydrocortisone, which is thought to have sufficient mineralocorticoid effect, is unclear. Differences among the agents are discussed separately. (See <a class="local">'Type (hydrocortisone preferred)'</a> below.)</p><p></p><p class="headingAnchor" id="H133305900"><span class="h3">Studies that showed no mortality benefit</span><span class="headingEndMark"> — </span>Several major randomized trials demonstrated faster resolution of shock <strong>without</strong> a mortality benefit from the administration of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Corticosteroid Therapy of Septic Shock (CORTICUS)</strong> – In this 2008 trial of 499 patients with septic shock (regardless of pressor dependency) <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> (50 mg) or placebo was administered intravenously every six hours for five days [<a href="#rid47">47</a>]. While hydrocortisone administration resulted in a faster reversal of shock (3.3 versus 5.8 days), hydrocortisone did <strong>not</strong> improve 28-day mortality (35 versus 32 percent in the placebo group). Outcomes were similar in the two pre-defined subgroups: patients with inadequate adrenal reserve and patients with adequate adrenal reserve. Hydrocortisone also resulted in an increased incidence of new infection that did not reach statistical significance (odds ratio 1.27, 95% CI 0.96-1.68). The trial was criticized for the lower than expected placebo-group mortality (32 percent versus the anticipated 50 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">Hydrocortisone</a><strong> for the prevention of septic shock (HYPRESS)</strong> – In this 2016 trial, 353 patients who had severe sepsis but without septic shock were randomized to receive hydrocortisone or placebo [<a href="#rid48">48</a>].The definition of severe sepsis was based upon the older definition of sepsis but comprised of patients with evidence of infection, at least two indices of the systemic inflammatory response syndrome criteria  (<a class="graphic graphic_table graphicRef69207" href="/z/d/graphic/69207.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef76149" href="/z/d/graphic/76149.html" rel="external">table 2</a>) and evidence of organ dysfunction present for no longer than 48 hours. Approximately half of patients had hospital-acquired sepsis. Compared with placebo, an infusion of hydrocortisone 200 mg daily for five days followed by tapering until day 11 had no significant effect on progression to septic shock or mortality. Hydrocortisone was associated with an increased rate of hyperglycemia (91 versus 82 percent) and a nonsignificant increase in the rate of infections (22 versus 17 percent) and muscle weakness (31 versus 24 percent). Criticisms of this trial included the exclusion of patients with septic shock and the inadequate assessment of CIRCI. (See  <a class="medical medical_review" href="/z/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis", section on 'Definitions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of Early </strong><a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">Vasopressin</a><strong> versus </strong><a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">Norepinephrine</a><strong> on Kidney Failure in Patients with Septic Shock (Vanish)</strong> – In this 2016 trial that compared vasopressin with norepinephrine in patients with septic shock, when compared with placebo, the addition of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> to either vasopressor did not result in a mortality benefit (28-day mortality 33 versus 29 percent for vasopressin group and 29 versus 26 percent for norepinephrine group) or have an effect on the rate of kidney failure [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL)</strong> – In this 2018 multicenter trial, 3800 patients (medical and surgical) who were mechanically ventilated and on vasopressors for at least four hours for septic shock were randomized to receive placebo or a continuous intravenous infusion of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> (200 mg per day for seven days, death, or discharge from the ICU, whichever came first) [<a href="#rid49">49</a>]. Corticotropin testing was not used to attempt to diagnose CIRCI. Hydrocortisone resulted in a faster resolution of shock (three versus four days), shorter duration of initial mechanical ventilation (six versus seven days), lower incidence of blood transfusion (37 versus 42 percent), and possibly, number of days alive outside of the ICU (58 versus 56 days). However, hydrocortisone administration did not improve 28- or 90-day mortality, overall number of mechanical ventilation-free days, rate of recurrent shock, or rate of renal replacement therapy. Hydrocortisone infusion did not increase the risk of new onset bacteremia or fungemia but patients did have higher rates of hyperglycemia and hypernatremia. A post-hoc analysis of this trial that applied updated Sepsis-3 or Sepsis-2 inclusion criteria to the study population still reported no mortality benefit from hydrocortisone [<a href="#rid65">65</a>].</p><p></p><p class="headingAnchor" id="H1782790"><span class="h3">Meta-analyses</span><span class="headingEndMark"> — </span>While older meta-analyses suggested that glucocorticoid therapy may benefit patients with septic shock [<a href="#rid66">66-71</a>], newer meta-analyses that included all the major randomized trials listed above (see <a class="local">'Studies that showed benefit'</a> above and <a class="local">'Studies that showed no mortality benefit'</a> above) have reported that systemic corticosteroids confer no or minimal mortality benefit but do shorten the duration of shock [<a href="#rid50">50,51,72-74</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 2018 meta-analysis of 22 trials that included 7297 patients, compared with placebo, corticosteroids did not improve short-term or long-term mortality (relative risk [RR] 0.98, 95% CI 0.89-1.08 and RR 0.96, 95% CI 0.91-1.02, respectively) [<a href="#rid50">50</a>]. Adverse events were greater in the group that received corticosteroids (hypernatremia, hyperglycemia) with substantial heterogeneity but the duration of shock was shorter (mean difference [MD] -1.52 days; 95% CI -1.72 to -1.32 days) as was the duration of mechanical ventilation (MD -1.38 days; 95% CI -1.96 to -0.80 days) and duration of ICU stay (MD -0.75 days; 95% CI; -1.34 to -0.17 days).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second meta-analysis of 42 trials including 10,194 patients, showed similar results [<a href="#rid51">51</a>]. While higher rates of shock reversal were reported compared with placebo (RR 1.26; 95% CI 1.12 to 1.42), corticosteroids resulted in minimal or no reduction in the risk of death (RR 0.93; 95% CI, 0.84-1.03, 1.8 percent absolute risk reduction at 28 days; RR 0.94; 95% CI 0.89-1.00, 2.2 percent risk reduction at 60 days). Also reported was a possible reduction in the length of hospital stay (-0.73 days; 95% CI -2.06 to 0.60), and a slight increase in the risk of hypernatremia (RR 1.64; 95% CI 1.32-2.03), hyperglycemia (1.16; 95% CI 1.08-1.24), and neuromuscular weakness (1.21; 95% CI 1.01-1.52).</p><p></p><p class="headingAnchor" id="H19"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H1330646853"><span class="h2">Type (hydrocortisone preferred)</span><span class="headingEndMark"> — </span>While older studies used <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, most major, well-conducted randomized trials used <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> as the glucocorticoid of choice in patients with sepsis and septic shock. Although some trials added <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a>, we do not typically add fludrocortisone because we believe that hydrocortisone alone has sufficient mineralocorticoid effect and absorption of the enterally administered drug is questionable in situations of compromised splanchnic perfusion [<a href="#rid75">75</a>]. Our decision to forego fludrocortisone is supported by others [<a href="#rid17">17</a>] and a trial (the Corticosteroids and Intensive Insulin Therapy for Septic Shock [COIITSS] trial) that randomly assigned 509 patients with septic shock to receive either hydrocortisone plus fludrocortisone or hydrocortisone alone [<a href="#rid76">76</a>]. There was no difference in any of the clinical outcomes. Nonetheless, some experts add fludrocortisone to hydrocortisone since two randomized trials demonstrated benefit in sick patients with septic shock (the French study and Activated Protein C and Corticosteroids for Human Septic Shock [APROCCHSS]) [<a href="#rid45">45,46</a>]. (See <a class="local">'Studies that showed benefit'</a> above.)</p><p>Compared with <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>, other pharmacologic glucocorticoids bind cortisol-binding globulin (CBG) poorly, resulting in greater amounts of free, physiologically active glucocorticoid and greater potency at any given dose. The different preparations vary widely in anti-inflammatory and mineralocorticoid potency  (<a class="graphic graphic_table graphicRef64138" href="/z/d/graphic/64138.html" rel="external">table 3</a>). Thus, if administering another glucocorticoid, the clinician should be familiar with the potency of that agent relative to hydrocortisone.</p><p class="headingAnchor" id="H1783135"><span class="h2">Dose</span><span class="headingEndMark"> — </span>We typically administer 200 to 300 mg per day of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> intravenously in divided doses (50 mg every six hours or 100 mg every eight hours). This is consistent with guidelines set out by the Society of Critical Care Medicine (SCCM) and European Society of Critical Care Medicine (EISCM) who recommend &lt;400 mg/day of hydrocortisone [<a href="#rid17">17</a>]. Most studies evaluating the effect of glucocorticoids in septic shock used hydrocortisone in divided doses rather than an infusion. Although one small prospective study showed less variability in blood glucose levels with continuous hydrocortisone infusions, the clinical benefit, from a mortality and shock reversal standpoint, remains unknown [<a href="#rid77">77</a>].</p><p>Dosing for methylprednisone is less well studied, but one suggested regimen is 40 to 60 mg daily intravenously in divided doses for a similar time period.</p><p><a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">Fludrocortisone</a> is administered as 0.05 mg once daily for 5 to 7 days (in combination with IV <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> or equivalent) [<a href="#rid45">45,46,78</a>].</p><p class="headingAnchor" id="H1783144"><span class="h2">Duration</span><span class="headingEndMark"> — </span>We typically administer five to seven days of therapy and have a tapered approach to withdrawal that is guided by the clinical response (eg, taper quickly following vasopressor withdrawal). Close observation of those patients whose steroid therapy is stopped without being tapered is warranted. This practice is consistent with SCCM/EISCM guidelines who recommend &lt;400 mg/day for ≥3 days [<a href="#rid17">17</a>]. There is no specific tapering regimen, and they vary widely.</p><p>There is no consensus regarding the optimal duration of treatment with, or withdrawal of, glucocorticoids. No large study has compared fixed-duration regimens to clinically-guided regimens, or tapering to abrupt cessation. However, in one small clinical study, abrupt cessation was associated with rebound of hemodynamic abnormalities and increased inflammatory markers [<a href="#rid79">79</a>]. In contrast, in another retrospective study reinitiation of vasopressor therapy was more common among patients in whom glucocorticoids were tapered compared with patients in whom glucocorticoid therapy was stopped abruptly [<a href="#rid80">80</a>].</p><p><a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">Fludrocortisone</a> is generally not tapered. </p><p class="headingAnchor" id="H3529884594"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111943.html" rel="external">"Society guideline links: Sepsis in children and adults"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Critical illness-related adrenal insufficiency</strong> – It is thought that absolute adrenal insufficiency is rare among critically ill patients. (See <a class="local">'Rationale'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Definition</strong> – While relative adrenal insufficiency (ie, critical illness-related corticosteroid insufficiency [CIRCI]) may be more common, a clear definition of CIRCI is lacking, so the incidence is unknown. (See <a class="local">'Critical illness-related corticosteroid insufficiency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mechanism</strong> – There are several mechanisms through which critical illness effects cortisol levels and function including activation and impairment of the hypothalamic-pituitary-adrenal (HPA) axis resulting in increased levels of circulating cortisol and adrenocortical hyporesponsiveness, respectively, and glucocorticoid resistance. (See <a class="local">'Mechanisms of adrenal insufficiency in sepsis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory testing</strong> – In general, most clinicians do not rely on laboratory testing to select glucocorticoid therapy in patients with septic shock because laboratory assays of plasma cortisol and adrenocorticotropic hormone (ACTH) stimulation testing are unreliable in critically ill patients and because testing has failed to consistently predict those who benefit from glucocorticoid use. With this caveat in mind, for clinicians who wish to assess adrenal reserve in critically ill patients, international guidelines endorse the use of a change in baseline cortisol at 60 min of &lt;9 mcg/dL after 250 mcg intravenously of cosyntropin (250 mcg; ie, high-dose ACTH stimulation) administration and a random plasma cortisol of &lt;10 mcg/dL as indicators of likely adrenal insufficiency. (See <a class="local">'Should adrenal reserve be assessed?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – We generally use the following guidelines when considering patients with sepsis and septic shock for glucocorticoid therapy (see <a class="local">'Glucocorticoid therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recommendations</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For adult patients with sepsis and septic shock, we suggest <strong>not</strong> routinely using intravenous glucocorticoid therapy as part of initial therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We use glucocorticoid therapy on a case-by-case basis in patients with refractory shock (defined as a systolic blood pressure &lt;90 mmHg for more than one hour following both adequate fluid resuscitation and vasopressor administration).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy data to support the approach</strong> – This approach is based upon randomized trials and meta-analyses that have consistently demonstrated that while glucocorticoid therapy leads to faster resolution of shock, there appears to be minimal or no effect on mortality; in addition, benefit is more likely to be seen in those who are severely ill rather than those with mild illness.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adverse effects</strong> – Potential adverse effects associated with the administration of steroids in this population include hypernatremia, hyperglycemia, and neuromuscular weakness. The risk of superinfection does not appear to be consistently elevated among studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – When the decision is made to use glucocorticoid therapy, we suggest <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> alone (&lt;400 mg per day in divided doses) rather than combined therapy with <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, addition of fludrocortisone (50 mcg via gastric tube once daily) is a reasonable alternative based upon two trials that showed a mortality benefit. We typically administer five to seven days of therapy and use a tapered approach to withdrawal that is guided by the clinical response. Close observation of patients whose steroid therapy is stopped without being tapered is warranted. (See <a class="local">'Administration'</a> above.)</p><p></p><p class="headingAnchor" id="H4149451109"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jordi Mancebo, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Stewart PM. The Adrenal Cortex. In: Williams Textbook of Endocrinology, Polonsky KS (Ed), Saunders, Philadelphia 2002. p.491.</li><li><a class="nounderline abstract_t">Lamberts SW, Bruining HA, de Jong FH. Corticosteroid therapy in severe illness. N Engl J Med 1997; 337:1285.</a></li><li><a class="nounderline abstract_t">Newsome HH, Rose JC. The response of human adrenocorticotrophic hormone and growth hormone to surgical stress. J Clin Endocrinol Metab 1971; 33:481.</a></li><li><a class="nounderline abstract_t">HUME DM, BELL CC, BARTTER F. Direct measurement of adrenal secretion during operative trauma and convalescence. Surgery 1962; 52:174.</a></li><li><a class="nounderline abstract_t">Vadas P, Pruzanski W. Plasma cortisol levels in patients with septic shock. Crit Care Med 1991; 19:300.</a></li><li><a class="nounderline abstract_t">Boonen E, Vervenne H, Meersseman P, et al. Reduced cortisol metabolism during critical illness. N Engl J Med 2013; 368:1477.</a></li><li><a class="nounderline abstract_t">Beishuizen A, Thijs LG, Vermes I. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 2001; 27:1584.</a></li><li><a class="nounderline abstract_t">Hammond GL, Smith CL, Paterson NA, Sibbald WJ. A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab 1990; 71:34.</a></li><li><a class="nounderline abstract_t">Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001; 16:1037.</a></li><li><a class="nounderline abstract_t">Franchimont D, Martens H, Hagelstein MT, et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999; 84:2834.</a></li><li><a class="nounderline abstract_t">WERK EE Jr, MACGEE J, SHOLITON LJ. EFFECT OF DIPHENYLHYDANTOIN ON CORTISOL METABOLISM IN MAN. J Clin Invest 1964; 43:1824.</a></li><li><a class="nounderline abstract_t">Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983; 1:1270.</a></li><li><a class="nounderline abstract_t">Malerba G, Romano-Girard F, Cravoisy A, et al. Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 2005; 31:388.</a></li><li><a class="nounderline abstract_t">Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293.</a></li><li><a class="nounderline abstract_t">Cohen J, Pretorius CJ, Ungerer JP, et al. Glucocorticoid Sensitivity Is Highly Variable in Critically Ill Patients With Septic Shock and Is Associated With Disease Severity. Crit Care Med 2016; 44:1034.</a></li><li><a class="nounderline abstract_t">Burry LD, Wax RS. Role of corticosteroids in septic shock. Ann Pharmacother 2004; 38:464.</a></li><li><a class="nounderline abstract_t">Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med 2017; 43:1751.</a></li><li><a class="nounderline abstract_t">MELBY JC, SPINK WW. Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. J Clin Invest 1958; 37:1791.</a></li><li><a class="nounderline abstract_t">Bouachour G, Roy PM, Guiraud MP. The repetitive short corticotropin stimulation test in patients with septic shock. Ann Intern Med 1995; 123:962.</a></li><li><a class="nounderline abstract_t">Sibbald WJ, Short A, Cohen MP, Wilson RF. Variations in adrenocortical responsiveness during severe bacterial infections. Unrecognized adrenocortical insufficiency in severe bacterial infections. Ann Surg 1977; 186:29.</a></li><li><a class="nounderline abstract_t">Schein RM, Sprung CL, Marcial E, et al. Plasma cortisol levels in patients with septic shock. Crit Care Med 1990; 18:259.</a></li><li><a class="nounderline abstract_t">Moran JL, Chapman MJ, O'Fathartaigh MS, et al. Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock. Intensive Care Med 1994; 20:489.</a></li><li><a class="nounderline abstract_t">Briegel J, Schelling G, Haller M, et al. A comparison of the adrenocortical response during septic shock and after complete recovery. Intensive Care Med 1996; 22:894.</a></li><li><a class="nounderline abstract_t">Annane D, Maxime V, Ibrahim F, et al. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006; 174:1319.</a></li><li><a class="nounderline abstract_t">McKee JI, Finlay WE. Cortisol replacement in severely stressed patients. Lancet 1983; 1:484.</a></li><li><a class="nounderline abstract_t">Jurney TH, Cockrell JL Jr, Lindberg JS, et al. Spectrum of serum cortisol response to ACTH in ICU patients. Correlation with degree of illness and mortality. Chest 1987; 92:292.</a></li><li><a class="nounderline abstract_t">Span LF, Hermus AR, Bartelink AK, et al. Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 1992; 18:93.</a></li><li><a class="nounderline abstract_t">Jarek MJ, Legare EJ, McDermott MT, et al. Endocrine profiles for outcome prediction from the intensive care unit. Crit Care Med 1993; 21:543.</a></li><li><a class="nounderline abstract_t">Drucker D, Shandling M. Variable adrenocortical function in acute medical illness. Crit Care Med 1985; 13:477.</a></li><li><a class="nounderline abstract_t">Rothwell PM, Lawler PG. Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 1995; 23:78.</a></li><li><a class="nounderline abstract_t">Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991; 337:582.</a></li><li><a class="nounderline abstract_t">Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629.</a></li><li><a class="nounderline abstract_t">Khan T, Kupfer Y, Tessler S. Free cortisol and critically ill patients. N Engl J Med 2004; 351:395.</a></li><li><a class="nounderline abstract_t">Ho JT, Al-Musalhi H, Chapman MJ, et al. Septic shock and sepsis: a comparison of total and free plasma cortisol levels. J Clin Endocrinol Metab 2006; 91:105.</a></li><li><a class="nounderline abstract_t">Vassiliadi DA, Ilias I, Tzanela M, et al. Interstitial cortisol obtained by microdialysis in mechanically ventilated septic patients: correlations with total and free serum cortisol. J Crit Care 2013; 28:158.</a></li><li><a class="nounderline abstract_t">Venkatesh B, Mortimer RH, Couchman B, Hall J. Evaluation of random plasma cortisol and the low dose corticotropin test as indicators of adrenal secretory capacity in critically ill patients: a prospective study. Anaesth Intensive Care 2005; 33:201.</a></li><li><a class="nounderline abstract_t">Loisa P, Uusaro A, Ruokonen E. A single adrenocorticotropic hormone stimulation test does not reveal adrenal insufficiency in septic shock. Anesth Analg 2005; 101:1792.</a></li><li><a class="nounderline abstract_t">Briegel J, Sprung CL, Annane D, et al. Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. Intensive Care Med 2009; 35:2151.</a></li><li><a class="nounderline abstract_t">Allolio B, Dörr H, Stuttmann R, et al. Effect of a single bolus of etomidate upon eight major corticosteroid hormones and plasma ACTH. Clin Endocrinol (Oxf) 1985; 22:281.</a></li><li><a class="nounderline abstract_t">Bouachour G, Tirot P, Gouello JP, et al. Adrenocortical function during septic shock. Intensive Care Med 1995; 21:57.</a></li><li><a class="nounderline abstract_t">Annane D, Sébille V, Troché G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038.</a></li><li><a class="nounderline abstract_t">Lipiner-Friedman D, Sprung CL, Laterre PF, et al. Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med 2007; 35:1012.</a></li><li><a class="nounderline abstract_t">Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med 2003; 31:141.</a></li><li><a class="nounderline abstract_t">Siraux V, De Backer D, Yalavatti G, et al. Relative adrenal insufficiency in patients with septic shock: comparison of low-dose and conventional corticotropin tests. Crit Care Med 2005; 33:2479.</a></li><li><a class="nounderline abstract_t">Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862.</a></li><li><a class="nounderline abstract_t">Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med 2018; 378:809.</a></li><li><a class="nounderline abstract_t">Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111.</a></li><li><a class="nounderline abstract_t">Keh D, Trips E, Marx G, et al. Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial. JAMA 2016; 316:1775.</a></li><li><a class="nounderline abstract_t">Venkatesh B, Finfer S, Cohen J, et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med 2018; 378:797.</a></li><li><a class="nounderline abstract_t">Rygård SL, Butler E, Granholm A, et al. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2018; 44:1003.</a></li><li><a class="nounderline abstract_t">Rochwerg B, Oczkowski SJ, Siemieniuk RAC, et al. Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis. Crit Care Med 2018; 46:1411.</a></li><li><a class="nounderline abstract_t">Casserly B, Gerlach H, Phillips GS, et al. Low-dose steroids in adult septic shock: results of the Surviving Sepsis Campaign. Intensive Care Med 2012; 38:1946.</a></li><li><a class="nounderline abstract_t">Lamontagne F, Rochwerg B, Lytvyn L, et al. Corticosteroid therapy for sepsis: a clinical practice guideline. BMJ 2018; 362:k3284.</a></li><li><a class="nounderline abstract_t">Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984; 311:1137.</a></li><li><a class="nounderline abstract_t">Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653.</a></li><li><a class="nounderline abstract_t">Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317:659.</a></li><li><a class="nounderline abstract_t">Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645.</a></li><li><a class="nounderline abstract_t">Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723.</a></li><li><a class="nounderline abstract_t">Yildiz O, Doganay M, Aygen B, et al. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002; 6:251.</a></li><li><a class="nounderline abstract_t">Beigel J, Eichacker P. Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency. ACP J Club 2003; 138:44.</a></li><li><a class="nounderline abstract_t">Rubenfeld, GD. When survival is not the same as mortality. Critical Care Alert 2003; 10:113.</a></li><li><a class="nounderline abstract_t">Eisen LA. Epoetin alfa in critically ill patients. N Engl J Med 2007; 357:2516; author reply 2516.</a></li><li><a class="nounderline abstract_t">Bosch NA, Teja B, Law AC, et al. Comparative Effectiveness of Fludrocortisone and Hydrocortisone vs Hydrocortisone Alone Among Patients With Septic Shock. JAMA Intern Med 2023; 183:451.</a></li><li><a class="nounderline abstract_t">Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA 2016; 316:509.</a></li><li><a class="nounderline abstract_t">Venkatesh B, Finfer S, Cohen J, et al. Hydrocortisone Compared with Placebo in Patients with Septic Shock Satisfying the Sepsis-3 Diagnostic Criteria and APROCCHSS Study Inclusion Criteria: A Post Hoc Analysis of the ADRENAL Trial. Anesthesiology 2019; 131:1292.</a></li><li><a class="nounderline abstract_t">Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301:2362.</a></li><li><a class="nounderline abstract_t">Minneci PC, Deans KJ, Eichacker PQ, Natanson C. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 2009; 15:308.</a></li><li><a class="nounderline abstract_t">Minneci PC, Deans KJ, Natanson C. Corticosteroid therapy for severe sepsis and septic shock. JAMA 2009; 302:1643; author reply 1644.</a></li><li><a class="nounderline abstract_t">Minneci PC, Deans KJ, Natanson C. Corticosteroid therapy for severe sepsis and septic shock. JAMA 2009; 302:1643; author reply 1644.</a></li><li><a class="nounderline abstract_t">Sligl WI, Milner DA Jr, Sundar S, et al. Safety and efficacy of corticosteroids for the treatment of septic shock: A systematic review and meta-analysis. Clin Infect Dis 2009; 49:93.</a></li><li><a class="nounderline abstract_t">Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for treating sepsis. Cochrane Database Syst Rev 2015; :CD002243.</a></li><li><a class="nounderline abstract_t">Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst Rev 2019; 12:CD002243.</a></li><li><a class="nounderline abstract_t">Lyu QQ, Chen QH, Zheng RQ, et al. Effect of Low-Dose Hydrocortisone Therapy in Adult Patients With Septic Shock: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials. J Intensive Care Med 2020; 35:971.</a></li><li><a class="nounderline abstract_t">Pirracchio R, Annane D, Waschka A. Patient-Level Meta-Analysis of Low-Dose Hydrocortisone in Adults with Septic Shock. NEJM Evid 2023; 2.</a></li><li><a class="nounderline abstract_t">Clore J, Schoolwerth A, Watlington CO. When is cortisol a mineralocorticoid? Kidney Int 1992; 42:1297.</a></li><li><a class="nounderline abstract_t">COIITSS Study Investigators, Annane D, Cariou A, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010; 303:341.</a></li><li><a class="nounderline abstract_t">Weber-Carstens S, Deja M, Bercker S, et al. Impact of bolus application of low-dose hydrocortisone on glycemic control in septic shock patients. Intensive Care Med 2007; 33:730.</a></li><li><a class="nounderline abstract_t">Renaud B, Buda M, Lewis BD, Pujol JF. Effects of 5,6-dihydroxytryptamine on tyrosine-hydroxylase activity in central catecholaminergic neurons of the rat. Biochem Pharmacol 1975; 24:1739.</a></li><li><a class="nounderline abstract_t">Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167:512.</a></li><li><a class="nounderline abstract_t">Carabetta S, Allen B, Cannon C, Johnson T. Abrupt Discontinuation Versus Taper of Hydrocortisone in Patients With Septic Shock. Ann Pharmacother 2023; 57:375.</a></li></ol></div><div id="topicVersionRevision">Topic 1654 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Stewart PM. The Adrenal Cortex. In: Williams Textbook of Endocrinology, Polonsky KS (Ed), Saunders, Philadelphia 2002. p.491.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9345079" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Corticosteroid therapy in severe illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4328338" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The response of human adrenocorticotrophic hormone and growth hormone to surgical stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14449954" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Direct measurement of adrenal secretion during operative trauma and convalescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846570" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Plasma cortisol levels in patients with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23506003" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Reduced cortisol metabolism during critical illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11685298" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2370299" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11393780" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443688" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14207774" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : EFFECT OF DIPHENYLHYDANTOIN ON CORTISOL METABOLISM IN MAN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6134053" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Influence of sedation on mortality in critically ill multiple trauma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15703896" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19573904" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26963327" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Glucocorticoid Sensitivity Is Highly Variable in Critically Ill Patients With Septic Shock and Is Associated With Disease Severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14970369" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Role of corticosteroids in septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28940011" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13611047" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7486498" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The repetitive short corticotropin stimulation test in patients with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/195542" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Variations in adrenocortical responsiveness during severe bacterial infections. Unrecognized adrenocortical insufficiency in severe bacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2302948" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Plasma cortisol levels in patients with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7995865" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8905423" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A comparison of the adrenocortical response during septic shock and after complete recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16973979" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnosis of adrenal insufficiency in severe sepsis and septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6131207" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cortisol replacement in severely stressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3038477" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Spectrum of serum cortisol response to ACTH in ICU patients. Correlation with degree of illness and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1613205" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8472574" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Endocrine profiles for outcome prediction from the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2986907" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Variable adrenocortical function in acute medical illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8001391" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prediction of outcome in intensive care patients using endocrine parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1671944" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cortisol response to corticotropin and survival in septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15084695" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Measurements of serum free cortisol in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15269323" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Free cortisol and critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263835" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Septic shock and sepsis: a comparison of total and free plasma cortisol levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22981531" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Interstitial cortisol obtained by microdialysis in mechanically ventilated septic patients: correlations with total and free serum cortisol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15960402" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evaluation of random plasma cortisol and the low dose corticotropin test as indicators of adrenal secretory capacity in critically ill patients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16301260" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A single adrenocorticotropic hormone stimulation test does not reveal adrenal insufficiency in septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19760208" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2983910" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of a single bolus of etomidate upon eight major corticosteroid hormones and plasma ACTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7560475" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adrenocortical function during septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10697064" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17334243" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adrenal function in sepsis: the retrospective Corticus cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12545007" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Adrenal insufficiency during septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16276169" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Relative adrenal insufficiency in patients with septic shock: comparison of low-dose and conventional corticotropin tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12186604" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29490185" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hydrocortisone plus Fludrocortisone for Adults with Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184957" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hydrocortisone therapy for patients with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27695824" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29347874" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Adjunctive Glucocorticoid Therapy in Patients with Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29761216" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29979221" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23064466" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Low-dose steroids in adult septic shock: results of the Surviving Sepsis Campaign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30097460" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Corticosteroid therapy for sepsis: a clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6384785" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3306374" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2888017" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9559600" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Reversal of late septic shock with supraphysiologic doses of hydrocortisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10321661" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12133187" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Physiological-dose steroid therapy in sepsis [ISRCTN36253388].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614129" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : When survival is not the same as mortality</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18084814" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Epoetin alfa in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36972033" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Comparative Effectiveness of Fludrocortisone and Hydrocortisone vs Hydrocortisone Alone Among Patients With Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27483065" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31651531" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hydrocortisone Compared with Placebo in Patients with Septic Shock Satisfying the Sepsis-3 Diagnostic Criteria and APROCCHSS Study Inclusion Criteria: A Post Hoc Analysis of the ADRENAL Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19509383" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19416302" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19843895" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Corticosteroid therapy for severe sepsis and septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19843895" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Corticosteroid therapy for severe sepsis and septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19489712" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Safety and efficacy of corticosteroids for the treatment of septic shock: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26633262" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Corticosteroids for treating sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31808551" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Corticosteroids for treating sepsis in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30270720" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effect of Low-Dose Hydrocortisone Therapy in Adult Patients With Septic Shock: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Patient-Level Meta-Analysis of Low-Dose Hydrocortisone in Adults with Septic Shock</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1474763" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : When is cortisol a mineralocorticoid?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20103758" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325831" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Impact of bolus application of low-dose hydrocortisone on glycemic control in septic shock patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effects of 5,6-dihydroxytryptamine on tyrosine-hydroxylase activity in central catecholaminergic neurons of the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12426230" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35927963" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Abrupt Discontinuation Versus Taper of Hydrocortisone in Patients With Septic Shock.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
